| DESCRIPTION | - BELLADONNA, J Immunol, (20020000), vol. 168, pages 5448 - 5454 | - |
| DESCRIPTION | - CHEMICAL ABSTRACTS, Database accession no. 477202-00-9 | - |
| DESCRIPTION | - CHEMICAL ABSTRACTS, Database accession no. 745013-59-6 | - |
| DESCRIPTION | - EISENRING et al., Nat Immunol, (20100000), vol. 11, pages 1030 - 1038 | - |
| DESCRIPTION | - GRAZIANI et al., Pharmacol Res, (20120100), vol. 65, no. 1, pages 9 - 22 | - |
| DESCRIPTION | - HODI et al., N Engl J Med, (20100000), vol. 363, pages 711 - 723 | - |
| DESCRIPTION | - PEGGS et al., J Exp Med, (20090000), vol. 206, pages 1717 - 1725 | - |
| DESCRIPTION | - SCHMIDT, Curr Opin Drug Discov Devel, (20090000), vol. 12, pages 284 - 295 | - |
| DESCRIPTION | - SOFIETTI et al., J Neurol, (20020000), vol. 249, pages 1357 - 1369 | - |
| DESCRIPTION | - TRINCHIERI, Nat Rev Immunol, (20030000), vol. 3, pages 133 - 146 | - |
| OPPOSITION | - Ahmet Murat Aydin et al., "Spotlight on atezolizumab and its potential in the treatment of advanced urothelial bladder cancer", OncoTargets and Therapy, (20170000), vol. 10, pages 1478 - 1502, XP055904401 | - |
| OPPOSITION | - Anthony Markham et al., "Cemiplimab: first global approval", Drugs, (20180000), vol. 78, pages 1841 - 1846, XP055904393 | - |
| OPPOSITION | - BERENBAUM, "Synergy, additivism and antagonism in immunosuppression, A Critical Review", Clin. Exp. Immunol, (19770000), vol. 28, pages 1 - 18, XP055363834 | - |
| OPPOSITION | - BERENBAUM, "Synergy, additivism and antagonism in immunosuppression", Clinical Experimental Immunology, (19770000), vol. 28, pages 1 - 18, XP055363834 | - |
| OPPOSITION | - CHOI et al., "Strengthening of antitumor immune memory and prevention of thymic atrophy mediated by adenovirus expressing IL-12and GM-CSF", Gene Therapy, (20120000), vol. 19, pages 711 - 723, XP055904334 | - |
| OPPOSITION | - COLOMBO et al., "Amount of interleukin 12 available at the tumor site is critical for tumor regression", Cancer Reasearch, (19960000), vol. 56, pages 2531 - 2534, XP002628043 | - |
| OPPOSITION | - EGILMEZ et al., "Tumor-Resident CD 8+ T- cell : The Critical Catalyst in IL -12-Mediated Reversal of Tumor Immune Suppression", Arch. Immunol. Ther. Exp., (20100000), vol. 58, pages 399 - 405, XP055903211 | - |
| OPPOSITION | - Flemming, Alexandra, "PD1 makes waves in anticancer immunotherapy", Nature Reviews | Drug Discovery, (20120801), vol. 11, page 1, XP055903835 | - |
| OPPOSITION | - HUANG et al., "The PD-1/B7-H1 Pathway Modulates theNatural Killer Cells versus Mouse Glioma Stem Cells", PLoS ONE, (20150000), vol. 10, no. 8, page e0134715, XP055904341 | - |
| OPPOSITION | - "InvivoGen review:", Immunoglobulin G, (20110000), XP055904338 | - |
| OPPOSITION | - Javier Corzoft, "Time, the forgotten dimension of ligand binding teaching", Biochemistry and Molecular Biology Education, (20060000), vol. 34, no. 6, pages 413 - 416, XP055903792 | - |
| OPPOSITION | - J.L. BRAMSON ET AL, "Direct intratumoral injection of an adenovirus expressing Interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of Interleukin-12", HUMAN GENE THERAPY, Mary Ann Liebert, Inc. Publishers, GB, GB , (19961020), vol. 07., ISSN 1043-0342, pages 1995 - 2002., XP002093895 | - |
| OPPOSITION | - KUMAR et al., "Preclinical characterization of dostarlimab, a therapeutic anti-PD-1 antibody with potent activity to enhance immune function in in vitro cellular assays and in vivo animal models", mAbs, (20210000), vol. 13, no. 1, pages 1 - 12, XP055904397 | - |
| OPPOSITION | - Laurence Zitvogel et al., "Cancer immunotherapy of established tumors with IL -12. Effective delivery by genetically engineered fibroblasts", The Journal of Immunology, (19950000), vol. 155, pages 1393 - 1403, XP055904389 | - |
| OPPOSITION | - Lissoni P, Fumagalli E, Malugani F, Ardizzoia A, Bucovec R, Tancini G, Gardani G S, "Stimulation of IL-12 secretion by GM-CSF in advanced cancer patients", JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS., WICHTIG EDITORE, MILAN., IT, IT , (20010401), vol. 15, no. 2, ISSN 0393-974X, pages 163 - 165, XP093127137 | - |
| OPPOSITION | - MANGSBO et al., "Enhanced tumor eradication by combining CTLA- 4 or PD-1 blockade with CpG Therapy", Journal of Immunotherapy, (20100000), vol. 33, no. 3, pages 225 - 235, XP009144370 | - |
| OPPOSITION | - Mangsbo et al., "Enhanced Tumor Eradication by Combining CTLA-4 or PD-1 Blockade With CpG Therapy", Journal of Immunotherapy, US , (20100401), vol. 33, no. 3, ISSN 1524-9557, pages 225 - 235, XP009144370 | - |
| OPPOSITION | - Mangsbo Sara M; Sandin Linda C; Anger Kerstin; Korman Alan J; Loskog Angelica; Totterman Thomas H, "Enhanced Tumor Eradication by Combining CTLA-4 or PD-1 Blockade With CpG Therapy", Journal of Immunotherapy, Lippincott Williams & Wilkins, US, US , (20100401), vol. 33, no. 3, ISSN 1524-9557, pages 225 - 235, XP009144370 | - |
| OPPOSITION | - Mingli Xu et al, "Regulation of Antitumor Immune Responses by the IL-12 Family Cytokines, IL-12, IL-23, and IL-27", Clinical and Developmental Immunology, (20100000), vol. 832454, pages 1 - 9, XP055904330 | - |
| OPPOSITION | - Nejat K. Egilmez et al., "Controiled-release Particulate Cytokine Adjuvants for Cancer Therapy", Endocrine, Metabolic & Immune Disorders - Drug Targets, (20070000), vol. 7, pages 266 - 270, XP055904333 | - |
| OPPOSITION | - PAVLIN et al., "Local and systemic antitumor effect of intratumoral and peritumoral IL -12 electrogene therapy on murine sarcoma", Cancer Biology & Therapy, (20090000), vol. 8, pages 2112 - 2120, XP055903191 | - |
| OPPOSITION | - PEREZ-GRACIA et al., "Clinical development of combination strategies in immunotherapy: are we ready for more than on investigational product in an early clinical trial?", Immunotherapy, (20090000), vol. 1, no. 5, pages 845 - 853, XP055904410 | - |
| OPPOSITION | - PICARDO et al., "Structure and optimization of checkpoint inhibitors", Cancers, (20190000), vol. 12, no. 38, pages 1 - 15, XP055904405 | - |
| OPPOSITION | - RAKHMILEVICH et al., "Cytokine gene therapy of cancer using gene gun technology: superior antitumor activity of interleukin-12", Human Gene Therapy, (19970000), vol. 8, pages 1303 - 1311, XP008002580 | - |
| OPPOSITION | - RAKHMILEVICH et al., "Gene gun-mediated IL -12 gene therapy induces antitumor effects in the absence of toxicity: a direct comparison with systemic IL -12 protein therapy", Journal of Immunotherapy, (19990000), vol. 22, pages 135 - 144, XP001073440 | - |
| OPPOSITION | - SAFFRAN et al., "Immunotherapy of established tumors in mice by intratumoral injection of interleukin-2 plasmid DNA: Induction of CD 8+ T- cell immunity", Cancer Gene Therapy, (19980000), vol. 5, pages 321 - 330, XP055904373 | - |
| OPPOSITION | - Schmidt SR, "Fusion-proteins as biopharmaceuticals--applications and challenges", CURRENT OPINION IN DRUG DISCOVERY AND DEVELOPMENT, CURRENT DRUGS, LONDON, GB, GB , (20090301), vol. 12, no. 2, ISSN 1367-6733, pages 284 - 295, XP009132026 | - |
| OPPOSITION | - TAHARA et al., "Effective eradication of established murine tumors with IL -12 gene therapy using a polycistronic retroviral vector", The Journal of Immunology, (19950000), vol. 154, pages 6466 - 6474, XP002049440 | - |
| OPPOSITION | - VOM BERG, "Interleukin-12 in Combination with CTLA-4 Blockade Leads to T- cell Dependent Rejection of Advanced Stage Glioma", Dissertation, (20110000), XP055903215 | - |
| OPPOSITION | - Vom Berg Johannes, "Interleukin-12 in Combination with CTLA-4 Blockade Leads to T-cellDependent Rejection of Advanced Stage Glioma", Dissertation, (20110101), XP055903215 | - |
| OPPOSITION | - WATANABE et al., "Intradermal delivery of IL -12 naked DNA induces systemic NK cell activation and Th1 response in vivo that is independent of endogenous IL -12 production", THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, (19990000), vol. 163, pages 1943 - 1950, XP055904360 | - |
| OPPOSITION | - WEBER et al., "Interleukin-12 gene transfer results in CD 8- dependent regression of murine CT26 liver tumors", Annals of Surgical Oncology, (19980000), vol. 6, pages 186 - 194, XP019369885 | - |
| OPPOSITION | - BECKMAN et al., "Antibody constructs in cancer therapy", Cancer, (20060000), vol. 109, no. 2, doi:10.1002/cncr.22402, pages 170 - 179, XP071125975 | |
| OPPOSITION | - SELIGER et al., "The expression, function, and clinical relevance of the B7 family members in cancer", Cancer Immunol. Immunother., (20120000), vol. 61, doi:10.1007/s00262-012-1293-6, pages 1327 - 1341, XP035088703 | |
| OPPOSITION | - SHIRABE et al., "Tumor-infiltrating lymphocytes and hepatocellular carcinoma: pathology and clinical management", International Journal of Clinical Oncology, (20100000), vol. 15, doi:10.1007/s10147-010-0131-0, pages 552 - 558, XP019867855 | |
| OPPOSITION | - TOPALIAN et al., "Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity", Current Opinion in Immunology, (20120000), vol. 24, doi:10.1016/j.coi.2011.12.009, pages 207 - 212, XP002714810 | |
| OPPOSITION | - Eksioglu, E.A. Mahmood, S.S. Chang, M. Reddy, V., "GM-CSF promotes differentiation of human dendritic cells and T lymphocytes toward a predominantly type 1 proinflammatory response", Experimental hematology, Elsevier Inc., US, US , (20070726), vol. 35, no. 8, doi:10.1016/j.exphem.2007.05.001, ISSN 0301-472X, pages 1163 - 1171, XP022171063 | |
| OPPOSITION | - ZABALA et al., "Induction of immunosuppressive molecules and regulatory T cells counteract the antitumor effect of interleukin-12-based gene therapy in a transgenic mouse model of liver cancer", Journal of Hepatology, (20070000), vol. 47, pages 807 - 815, XP022331890 | |
| OPPOSITION | - Zabala, M. Lasarte, J.J. Perret, C. Sola, J. Berraondo, P. Alfaro, M. Larrea, E. Prieto, J. Kramer, M.G., "Induction of immunosuppressive molecules and regulatory T cells counteracts the antitumor effect of interleukin-12-based gene therapy in a transgenic mouse model of liver cancer", Journal of Hepatology, Elsevier, AMSTERDAM, NL, AMSTERDAM, NL , (20071106), vol. 47, no. 6, doi:10.1016/j.jhep.2007.07.025, ISSN 0168-8278, pages 807 - 815, XP022331890 | |
| OPPOSITION | - CHENG et al., "The PD-1/PD-L pathway is up-regulated during IL -12-induced suppression of EAE mediated by IFN-gamma", Journal of Neuroimmunology, (20070000), vol. 185, doi:10.1016/j.jneuroim.2007.01.012, pages 75 - 86, XP022009019 | |
| OPPOSITION | - SABEL et al., "Synergistic effect of intratumoral IL -12 and TNF- alpha microspheres: systemic anti-tumor immunity is mediated by both CD 8+ CTL and NK cells", Surgery, (20070000), vol. 142, no. 5, doi:10.1016/j.surg.2007.05.008, pages 749 - 760, XP022320882 | |
| OPPOSITION | - Sabel, M.S. Arora, A. Su, G. Mathiowitz, E. Reineke, J.J. Chang, A.E., "Synergistic effect of intratumoral IL-12 and TNF-@a microspheres: systemic anti-tumor immunity is mediated by both CD8+ CTL and NK cells", SURGERY, Mosby, Inc., US, US , (20071102), vol. 142, no. 5, doi:10.1016/j.surg.2007.05.008, ISSN 0039-6060, pages 749 - 760, XP022320882 | |
| OPPOSITION | - LIU et al., "Structural basis of anti-PD-L1 monoclonal antibody avelumab for tumor therapy", Cell Research, (20170000), vol. 27, doi:10.1038/cr.2016.102, pages 151 - 153, XP055537641 | |
| OPPOSITION | - QUETGLAS et al., "Immunotherapeutic Synergy Between Anti- CD 137 mAb and Intratumoral Administration of a Cytopathic Semliki Forest Virus Encoding IL -12", Molecular Therapy, (20120000), vol. 20, doi:10.1038/mt.2012.56, pages 1664 - 1675, XP055567366 | |
| OPPOSITION | - Quetglas et al., "Immunotherapeutic Synergy Between Anti-CD137 mAb and Intratumoral Administration of a Cytopathic Semliki Forest Virus Encoding IL-12", Molecular Therapy, US , (20120901), vol. 20, no. 9, doi:10.1038/mt.2012.56, ISSN 1525-0016, pages 1664 - 1675, XP055567366 | |
| OPPOSITION | - Eisenring et al., "IL-12 initiates tumor rejection via lymphoid tissue-inducer cells bearing the natural cytotoxicity receptor NKp46", Nature Immulogy, New York , (20101101), vol. 11, no. 11, doi:10.1038/ni.1947, ISSN 1529-2908, pages 1030 - 1038, XP055477741 | |
| OPPOSITION | - EISENRING et al., "IL -12 initiates tumor rejection via lymphoid tissue-inducer cells bearing the natural cytotoxicity receptor NKp46", Nature Immunology, vol. 11, doi:10.1038/ni.1947, (20100000), pages 1030 - 1038, XP055477741 | |
| OPPOSITION | - SHIMIZU et al., "Stimulation of CD 25+ CD 4+ regulatory T cells through GITR breaks immunological self-tolerance", Nature Immunology, (20020000), vol. 3, no. 2, doi:10.1038/ni759, pages 135 - 142, XP002247979 | |
| OPPOSITION | - Matthew Vanneman, Glenn Dranoff, "Combining immunotherapy and targeted therapies in cancer treatment", Nature Reviews Cancer, Nature Pub. Group, (20120101), vol. 12, no. 4, doi:10.1038/nrc3237, ISSN 1474175X, pages 237 - 251, XP055045378 | |
| OPPOSITION | - Pardoll Drew M., "The blockade of immune checkpoints in cancer immunotherapy", Nature Reviews Cancer, Nature Pub. Group, London, London , (20120322), vol. 12, no. 4, doi:10.1038/nrc3239, ISSN 1474-175X, pages 252 - 264, XP037114946 | |
| OPPOSITION | - PARDOLL et al., "The blockade of immune checkpoints in cancer immontherapy", Nature Reviews Cancer, (20120000), vol. 12, doi:10.1038/nrc3239, pages 252 - 264, XP037114946 | |
| OPPOSITION | - PARDOLL, "The blockade of immune checkpoints in cancer immunotherapy", Nature Reviews Cancer, (20120000), vol. 12, doi:10.1038/nrc3239, pages 252 - 264, XP037114946 | |
| OPPOSITION | - Lieping Chen, "Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity", Nature Reviews Immunology, Nature Pub. Group, (20040501), vol. 4, no. 5, doi:10.1038/nri1349, ISSN 14741733, pages 336 - 347, XP055141186 | |
| OPPOSITION | - LIU et al., "Study of the interactions of a novel monoclonal antibody, mAb059c, with the hPD-1 receptor", Scientific Reports, (20190000), vol. 9, doi:10.1038/s41598-019-54231-w, page 17830, XP055858008 | |
| OPPOSITION | - LIU et al., "Study of the interactions of a novel monoclonal antibody, mAb059c, with the hPD-1 receptor", Scientific Reports Nature Research, (20190000), vol. 9, doi:10.1038/s41598-019-54231-w, page 17830, XP055858008 | |
| OPPOSITION | - LIU et al., "In situ adenoviral interleukin 12 gene transfer confers potent and long-lasting cytotoxic immunity in glioma", Cancer Gene Therapy, (20020000), vol. 9, doi:10.1038/sj.cgt.7700399, pages 9 - 15, XP055046148 | |
| OPPOSITION | - LIU et al., "In situ adenoviral interleukin 12 gene transfer confers potent and long-lasting cytotoxic immunity in glioma", Cancer Gene Therapy, (20020000), vol. 9, no. 1, doi:10.1038/sj.cgt.7700399, pages 9 - 15, XP055046148 | |
| OPPOSITION | - Liu et al., "In situ adenoviral interleukin 12 gene transfer confers potent and long-lasting cytotoxic immunity in glioma", Cancer Gene Therapy, (20020101), vol. 9, no. 1, doi:10.1038/sj.cgt.7700399, ISSN 09291903, pages 9 - 15, XP055046148 | |
| OPPOSITION | - Yunhui Liu, Moneeb Ehtesham, Ken Samoto, Christopher J Wheeler, Reid C Thompson, Luis P Villarreal, Keith L Black, John S Yu, "In situ adenoviral interleukin 12 gene transfer confers potent and long-lasting cytotoxic immunity in glioma", Cancer Gene Therapy, Appleton & Lange, (20020101), vol. 9, no. 1, doi:10.1038/sj.cgt.7700399, ISSN 09291903, pages 9 - 15, XP055046148 | |
| OPPOSITION | - MAHVI et al., "Intratumoral injection of IL -12 plasmid DNA - results of a phase I/IB clinical trial", Cancer Gene Therapy, (20070000), vol. 14, doi:10.1038/sj.cgt.7701064, pages 717 - 723, XP055492519 | |
| OPPOSITION | - Shi, Et Al, "Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: what we do and don't know", Cell Research, (20060101), vol. 16, doi:10.1038/sj.cr.7310017, pages 126 - 133, XP055336332 | |
| OPPOSITION | - C P Chikkanna-Gowda, B J Sheahan, M N Fleeton, G J Atkins, "Regression of mouse tumours and inhibition of metastases following administration of a Semliki Forest virus vector with enhanced expression of IL-12", Gene Therapy, Macmillan Press Ltd., (20050801), vol. 12, no. 16, doi:10.1038/sj.gt.3302561, ISSN 09697128, pages 1253 - 1263, XP055014072 | |
| OPPOSITION | - WEBER, "Immune Checkpoint Proteins: A New Therapeutic Paradigm for Cancer - Preclinical Background: CTLA-4 and PD-1 Blockade", Seminars on Oncology, (20100000), vol. 37, no. 5, doi:10.1053/j.seminoncol.2010.09.005, pages 430 - 439, XP009177527 | |
| OPPOSITION | - ASCIERTO et al., "Clinical experiences with anti- CD 137 and anti-PD1 therapeutic antibodies", Seminars in Oncology, (20100000), vol. 37, no. 5, doi:10.1053/j.seminoncol.2010.09.008, pages 508 - 516, XP008175440 | |
| OPPOSITION | - Ascierto et al., "Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies.", Seminars in Oncology, US , (20101001), vol. 27, no. 5, doi:10.1053/j.seminoncol.2010.09.008, ISSN 1532-8708, pages 508 - 516, XP008175440 | |
| OPPOSITION | - Ascierto Paolo A; Simeone Ester; Sznol Mario; Fu Yang-Xin; Melero Ignacio, "Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies.", Seminars in Oncology, Elsevier, US, US , (20101001), vol. 27, no. 5, doi:10.1053/j.seminoncol.2010.09.008, ISSN 1532-8708, pages 508 - 516, XP008175440 | |
| OPPOSITION | - Topalian et al., "Safety, activity, and immune correlates of anti-PD-1 antibody in cancer", The New England journal of medicine, US , (20120628), vol. 366, no. 26, doi:10.1056/NEJMoa1200690, ISSN 0028-4793, pages 2443 - 2454, XP055098235 | |
| OPPOSITION | - BRAHMER et al., "Safety and Activity and Anti-PD-L1 Antibody in Patients with Advanced Cancer", New Engl. J. Med., (20120000), vol. 366, doi:10.1056/NEJMoa1200694, pages 2455 - 2465, XP002685330 | |
| OPPOSITION | - Brahmer et al., "Safety and activity of anti-PD-L1 antibody in patients with advanced cancer", New England Journal of Medicine, US , (20120628), vol. 366, no. 26, doi:10.1056/NEJMoa1200694 , ISSN 1533-4406, pages 2455 - 2465, XP002685330 | |
| OPPOSITION | - Julie R. Brahmer, Scott S. Tykodi, Laura Q.M. Chow, Wen-Jen Hwu, Suzanne L. Topalian, Patrick Hwu, Charles G. Drake, Luis H. Camacho, John Kauh, Kunle Odunsi, Henry C. Pitot, Omid Hamid, Shailender Bhatia, Renato Martins, M.P.H., Keith Eaton, Shuming Chen, Theresa M. Salay, Suresh Alaparthy, Joseph F. Grosso, Alan J. Korman, Susan M. Parker, Shruti Agrawal, Stacie M. Goldberg, Drew M. Pardoll, Ashok Gupta, Jon M. Wigginton, "Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.", New England Journal of Medicine, The - NEJM, Massachusetts Medical Society, US, US , (20120628), vol. 366, no. 26, doi:10.1056/NEJMoa1200694 , ISSN 1533-4406, pages 2455 - 2465, XP002685330 | |
| OPPOSITION | - PUTZER BRIGITTE M ET AL, "Interleukin 12 and B7-1 costimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression", Proceedings of the National Academy of Sciences, National Academy of Sciences, (19970101), vol. 94, no. 20, doi:10.1073/pnas.94.20.10889, ISSN 0027-8424, pages 10889 - 10894, XP002421569 | |
| OPPOSITION | - PÜTZER et al., "Interleukin 12 and B7-1 costimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression", Proc. Natl. Acad. Sci. USA, (19970000), vol. 94, doi:10.1073/pnas.94.20.10889, pages 10889 - 10894, XP002421569 | |
| OPPOSITION | - OSHIKAWA et al., "Synergistic inhibition of tumor growth in a murine mammary adenocarcinoma model by combinational gene therapy using IL -12, pro- IL -18, and IL -1beta converting enzyme cDNA", Proceedings of the National Academy of the Sciences of the United States of America, (19990000), vol. 96, no. 23, doi:10.1073/pnas.96.23.13351, pages 13351 - 13356, XP055802761 | |
| OPPOSITION | - Lissoni Paolo, Perego Maristella, Veronese Elisabetta, Fumagalli Gabriele, Brivio Fernando, Colciago Massimo, Messina Giusy, Rovelli Franco, Brivio Rinaldo, Gardani Gianstefano, "Endocrine Effects of Erythropoietin in Cancer Patients", Hematology, (20041001), vol. 9, no. 5-6, doi:10.1080/10245330400001876, ISSN 1607-8454, pages 363 - 367, XP093127135 | |
| OPPOSITION | - RUDNICK et al., "Affinity and avidity in antibody-based tumor targeting", Cancer Biotherapy and Radiopharmaceuticals, (20090000), vol. 24, no. 2, doi:10.1089/cbr.2009.0627, pages 155 - 161, XP055069540 | |
| OPPOSITION | - WONG et al., "Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs", International Immunology, (20070000), vol. 19, doi:10.1093/intimm/dxm091, pages 1223 - 1234, XP009105472 | |
| OPPOSITION | - David A. Zaharoff, Kenneth W. Hance, Connie J. Rogers, Jeffrey Schlom, John W. Greiner, "Intratumoral Immunotherapy of Established Solid Tumors With Chitosan/IL-12 : ", Journal of Immunotherapy, Lippincott Williams & Wilkins, US, US , (20100901), vol. 33, no. 7, doi:10.1097/CJI.0b013e3181eb826d, ISSN 1524-9557, pages 697 - 705, XP055422609 | |
| OPPOSITION | - P. L. Triozzi, "Phase I Study of the Intratumoral Administration of Recombinant Canarypox Viruses Expressing B7.1 and Interleukin 12 in Patients with Metastatic Melanoma", Clinical Cancer Research, Association for Cancer Research, (20050601), vol. 11, no. 11, doi:10.1158/1078-0432.CCR-04-2283, ISSN 10780432, pages 4168 - 4175, XP055046157 | |
| OPPOSITION | - TRIOZZI et al., "Phase I study of the intratumoral administration of recombinant canarypox viruses expressing B7.1 and interleukin-12 in patients with metastatic melanoma", Clinical Cancer Research, (20050000), vol. 11, no. 11, doi:10.1158/1078-0432.CCR-04-2283, pages 4168 - 4175, XP055046157 | |
| OPPOSITION | - FECCI et al., "Systemic CTLA-4 blockade ameliorates glioma- induced changes to the CD 4+ T cell compartment without affecting regulatory T- Cell function", Clinical Cancer Research, (20070000), vol. 13, no. 7, doi:10.1158/1078-0432.CCR-06-2070, pages 2158 - 2467, XP055022031 | |
| OPPOSITION | - P. E. Fecci, Ochiai H., Mitchell D. A., Grossi P. M., Sweeney A. E., Archer G. E., Cummings T., Allison J. P., Bigner D. D., Sampson J. H., "Systemic CTLA-4 Blockade Ameliorates Glioma-Induced Changes to the CD4+ T Cell Compartment without Affecting Regulatory T-Cell Function", Clinical Cancer Research, Association for Cancer Research, (20070401), vol. 13, no. 7, doi:10.1158/1078-0432.CCR-06-2070, ISSN 10780432, pages 2158 - 2167, XP055022031 | |
| OPPOSITION | - Del Vecchio et al., "Interleukin-12: Biological Properties and Clinical Application", Clinical Cancer Research, US, (20070815), vol. 13, no. 16, doi:10.1158/1078-0432.CCR-07-0776, ISSN 1078-0432, pages 4677 - 4685, XP055903839 | |
| OPPOSITION | - B. Li, M. Vanroey, C. Wang, T.-H. T. Chen, A. Korman, K. Jooss, "Anti-Programmed Death-1 Synergizes with Granulocyte Macrophage Colony-Stimulating Factor-Secreting Tumor Cell Immunotherapy Providing Therapeutic Benefit to Mice with Established Tumors", Clinical Cancer Research, Association for Cancer Research, (20090301), vol. 15, no. 5, doi:10.1158/1078-0432.CCR-08-1825, ISSN 10780432, pages 1623 - 1634, XP055166457 | |
| OPPOSITION | - LI et al., "Anti-Programmed Death-1 Synergizes with Granulocyte Macrophage Colony- Stimulating Factor - Secreting Tumor Cell Immunotherapy Providing Therapeutic Benefit to Mice with Established Tumors", Clinical Cancer Res., (20090000), vol. 15, doi:10.1158/1078-0432.CCR-08-1825, pages 1623 - 1634, XP055166457 | |
| OPPOSITION | - YU et al., "Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumour activity mediated by interleukin-15 in a murine metastatic colon carcinoma model", Cancer Therapy: Preclinical, (20100000), vol. 16, no. 24, doi:10.1158/1078-0432.CCR-10-1966, pages 6019 - 6028, XP055123618 | |
| OPPOSITION | - CARSON et al., "Braking bad: blockade of inhibitory pathways improves interleukin-15 therapy", Clinical Cancer Research, (20100000), vol. 16, no. 24, doi:10.1158/1078-0432.CCR-10-2658, pages 5917 - 5919, XP055150942 | |
| OPPOSITION | - A. Patnaik, S. P. Kang, D. Rasco, K. P. Papadopoulos, J. Elassaiss-Schaap, M. Beeram, R. Drengler, C. Chen, L. Smith, G. Espino, K. Gergich, L. Delgado, A. Daud, J. A. Lindia, X. N. Li, R. H. Pierce, J. H. Yearley, D. Wu, O. Laterza, M. Lehnert, R. Iannone, A. W. Tolcher, "Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors", Clinical Cancer Research, Association for Cancer Research, US, US, (20151001), vol. 21, no. 19, doi:10.1158/1078-0432.CCR-14-2607, ISSN 1078-0432, pages 4286 - 4293, XP055370195 | |
| OPPOSITION | - ZHONG et al., "Induction, Selection and Expansion of Acute Myeloid Leukemia Reactive Autologous T Cells for Adoptive Immunotherapy", Blood, (20050000), vol. 106, doi:10.1182/blood.V106.11.1061.1061, page 1061, XP086665416 | |
| OPPOSITION | - Zhong et al., "Induction, Selection and Expansion of Acute Myeloid Leukemia Reactive Autologous T Cells for Adoptive Immunotherapy.", Blood, US , (20051116), vol. 106, no. 11, doi:10.1182/blood.V106.11.1061.1061, ISSN 0006-4971, page 1061, XP086665416 | |
| OPPOSITION | - Zhong Rui-kun; Ball Edward D., "Induction, Selection and Expansion of Acute Myeloid Leukemia Reactive Autologous T Cells for Adoptive Immunotherapy.", Blood, American Society of Hematology, US, US , (20051116), vol. 106, no. 11, doi:10.1182/blood.V106.11.1061.1061, ISSN 0006-4971, page 1061, XP086665416 | |
| OPPOSITION | - Mark J. Selby, Engelhardt John J., Johnston Robert J., Lu Li-Sheng, Han Minhua, Thudium Kent, Yao Dapeng, Quigley Michael, Valle Jose, Wang Changyu, Chen Bing, Cardarelli Pina M., Blanset Diann, Korman Alan J., "Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology", PLOS ONE, (20160909), vol. 11, no. 9, doi:10.1371/journal.pone.0161779, page e0161779, XP055389440 | |
| OPPOSITION | - Meghan E Turnis, Rooney Cliona M, "Enhancement of dendritic cells as vaccines for cancer", Immunotherapy, vol. 2, n. 6, doi:10.2217/imt.10.56, (20101101), pages 847 - 862, Immunotherapy, vol. 2, n. 6, URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3433954/pdf/nihms-400973.pdf, (20190703), XP055601773 | |
| OPPOSITION | - SIMEONE et al., "Immunomodulating antibodies in the treatment of metastatic melanoma: The experience with anti-CTLA-4, anti- CD 137, and anti-PD1", Journal of Immunotoxicology, (20120000), vol. 9, doi:10.3109/1547691X.2012.678021, pages 241 - 247, XP009181173 | |
| OPPOSITION | - EISENRING et al., IL -12 initiates tumor rejection via lymphoid tissue- D1 inducer cells bearing the natural cytotoxicity receptor NKp46, (20101100), XP055863544 | |
| OPPOSITION | - HAILE et al., "Tumor Cell Programmed Death Ligand 1-Mediated T Cell Suppression is Overcome by Coexpression of CD 80", Journal of Immunology, (20110000), vol. 186, doi:10.4049/jimmunol.1003682, pages 6822 - 6829, XP055863544 | |
| SEARCH | - MANGSBO SARA M ET AL, "Enhanced Tumor Eradication by Combining CTLA-4 or PD-1 Blockade With CpG Therapy", JOURNAL OF IMMUNOTHERAPY, LIPPINCOTT WILLIAMS & WILKINS, US, (20100401), vol. 33, no. 3, ISSN 1524-9557, pages 225 - 235, XP009144370 [Y] 1-13 * page 234, column 1, paragraph 3 - column 2, paragraph 2 * | - |
| SEARCH | - SABEL ET AL, "Synergistic effect of intratumoral IL-12 and TNF-alpha microspheres: systemic anti-tumor immunity is mediated by both CD8+ CTL and NK cells", SURGERY, C.V. MOSBY CO., ST. LOUIS, US, (20071102), vol. 142, no. 5, doi:10.1016/J.SURG.2007.05.008, ISSN 0039-6060, pages 749 - 760, XP022320882 [T] 1-13 * page 758, column r, lines 1-3, paragraph 2 * | |
| SEARCH | - YUNHUI LIU ET AL, "In situ adenoviral interleukin 12 gene transfer confers potent and long-lasting cytotoxic immunity in glioma", CANCER GENE THERAPY, (20020101), vol. 9, no. 1, doi:10.1038/sj.cgt.7700399, ISSN 0929-1903, pages 9 - 15, XP055046148 [Y] 1-13 * abstract * | |
| SEARCH | - ASCIERTO PAOLO A ET AL, "Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies", SEMINARS IN ONCO, ELSEVIER, US, vol. 27, no. 5, doi:10.1053/J.SEMINONCOL.2010.09.008, ISSN 1532-8708, (20101001), pages 508 - 516, (20101110), XP008175440 [Y] 1-13 * page 512, column 1, paragraph 2 * | |
| SEARCH | - P. L. TRIOZZI, "Phase I Study of the Intratumoral Administration of Recombinant Canarypox Viruses Expressing B7.1 and Interleukin 12 in Patients with Metastatic Melanoma", CLINICAL CANCER RESEARCH, (20050601), vol. 11, no. 11, doi:10.1158/1078-0432.CCR-04-2283, ISSN 1078-0432, pages 4168 - 4175, XP055046157 [A] 1-13 * abstract * * page 4172, column l, paragraph 1 * | |
| SEARCH | - P. E. FECCI ET AL, "Systemic CTLA-4 Blockade Ameliorates Glioma-Induced Changes to the CD4+ T Cell Compartment without Affecting Regulatory T-Cell Function", CLINICAL CANCER RESEARCH, (20070401), vol. 13, no. 7, doi:10.1158/1078-0432.CCR-06-2070, ISSN 1078-0432, pages 2158 - 2167, XP055022031 [A] 1-13 * the whole document * | |
| SEARCH | - ZHONG RUI-KUN ET AL, "Induction, selection and expansion of acute myeloid leukemia reactive autologous T cells for adoptive immunotherapy", BLOOD; 47TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; ATLANTA, GA, USA; DECEMBER 10 -13, 2005, AMERICAN SOCIETY OF HEMATOLOGY, US, (20051116), vol. 106, no. 11 part 1, ISSN 0006-4971, pages 1 - 2, XP009157602 [A] 1-13 * abstract * | |
